Compare CADL & BCAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CADL | BCAL |
|---|---|---|
| Founded | 1999 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 641.2M | 704.1M |
| IPO Year | 2021 | 2020 |
| Metric | CADL | BCAL |
|---|---|---|
| Price | $8.34 | $21.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 4 |
| Target Price | $22.11 | ★ $24.75 |
| AVG Volume (30 Days) | ★ 905.6K | 186.5K |
| Earning Date | 11-12-2026 | 10-28-2026 |
| Dividend Yield | N/A | ★ 2.24% |
| EPS Growth | 58.62 | ★ 777.27 |
| EPS | N/A | ★ 0.86 |
| Revenue | ★ $125,000.00 | N/A |
| Revenue This Year | N/A | $1.22 |
| Revenue Next Year | N/A | $6.66 |
| P/E Ratio | ★ N/A | $24.92 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.35 | $16.87 |
| 52 Week High | $14.00 | $22.41 |
| Indicator | CADL | BCAL |
|---|---|---|
| Relative Strength Index (RSI) | 36.89 | 46.21 |
| Support Level | $7.70 | $21.17 |
| Resistance Level | $9.42 | $21.87 |
| Average True Range (ATR) | 0.54 | 0.43 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 27.27 | 34.92 |
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
California BanCorp is a relationship-focused community bank offering commercial loan and deposit products, along with other services delivered directly or through strategic alliances, to business and individual customers in its target markets. The Company provides financial products and services to individuals, professionals, and small to medium-sized businesses through its branch and commercial banking offices serving California. Its lending products consist mainly of construction and land development loans, real estate loans, C&I loans, and consumer loans, and it is a Preferred SBA Lender, while its deposit products consist mainly of demand deposit, money market, and certificates of deposit. The Company operates in one reportable segment, commercial banking.